EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Brain accumulation of lactosylceramide characterizes GALC deficiency in a zebrafish model of Krabbe disease

Jessica Guerra, Mirella Belleri, Elisa Scalvini, Davide Capoferri, Chiara Tobia, Cosetta Ravelli, Marzia Corli, Nicole Bresciani, Josefina Casas, Gemma Fabrias, Michele Dei Cas, Marco Presta iD und 1 weitere

Brain · 03.10.2025 · 148 (10) · 3748-3762

DOI: 10.1093/brain/awaf150 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Brain, online erschienen am 30.04.2025. Verfasst von Jessica Guerra und 12 weiteren Autor:innen. Beteiligte Einrichtung: Unit of Experimental Oncology and Immunology, University of Brescia, Brescia 25123, Italy. Hauptthemen laut MEDLINE: Leukodystrophy, Globoid Cell, Galactosylceramidase, Brain, Lactosylceramides. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Associazione Italiana per la Ricerca sul Cancro, Next Generation EU, Fondazione Berlucchi.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Krabbe disease (KD) is an autosomal recessive sphingolipidosis due to mutations of the GALC gene encoding for the lysosomal β-galactosylceramidase (GALC) that removes β-galactose from β-galactosylceramide, β-lactosylceramide (LacCer) and the neurotoxic metabolite β-galactosylsphingosine (psychosine). At present, the accumulation of psychosine is thought to be the main cause of demyelination, neurodegeneration and neuroinflammation that characterize the early infantile KD with a 1.5–2-year median survival. Currently, the standard of care of KD is haematopoietic stem cell transplantation which, however, improves the lifespan of Krabbe patients only when performed before symptoms appear. Thus, a better understanding of the pathogenesis of KD is required for the development of more efficacious therapeutic approaches. This largely depends upon the availability of novel suitable animal models of the disease. Zebrafish (Danio rerio) represents a useful platform for the study of the mechanisms responsible for human hereditary diseases, including sphingolipidoses, and for the identification of new therapeutics. Two co-orthologues of human GALC have been identified in zebrafish, named galca and galcb. Here, we generated a mutant zebrafish line for each of the two co-orthologues by CRISPR/Cas9 genome editing. Galcb knockout (KO), but not galca KO, exerts a dramatic decrease of total GALC activity both in zebrafish embryos and in the brain of adult mutants. At 3–4 months post-fertilization, galcb KO zebrafish showed impaired locomotion and reduced lifespan. Gene expression analysis, immunohistochemistry, spectral confocal reflectance and transmission electron microscopy showed the presence of demyelination, neuroinflammation and neurodegeneration in the brain of galcb KO mutants. Notably, double galca/galcb KO did not cause a further worsening of the disease when compared with galcb KO mutants. Finally, targeted lipidomic analysis demonstrated a dramatic accumulation of the bioactive sphingolipid LacCer in the brain of both galcb KO and double galca/galcb KO mutants with a modest increase of psychosine levels. Accordingly, activation of LacCer-related signalling occurs in the brain of galcb KO animals. Furthermore, intraventricular injection of LacCer upregulates the expression of various proinflammatory markers and increase mpeg1-positive macrophage infiltration in the brain of 5 dpf zebrafish embryos. In conclusion, galcb KO zebrafish recapitulates several pathological features of KD and is characterized by the accumulation of the bioactive LacCer. This model sheds new light on a possible role of LacCer as a neuroinflammatory/neurodegenerative metabolite in KD with implications for the development of novel therapeutic strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukodystrophy, Globoid CellGalactosylceramidaseBrainLactosylceramidesAnimalsZebrafishDisease Models, AnimalAnimals, Genetically ModifiedPsychosine

Stichwörter der Autor:innen

Krabbe diseaselactosylceramidelipidomicssphingolipidosiszebrafishβ-galactosylceramidase

Substanzen

GalactosylceramidaseLactosylceramidesPsychosine

Autor:innen und Institutionen

  • Unit of Experimental Oncology and Immunology, University of Brescia, Brescia 25123, Italy.
  • Zebrafish Facility, University of Brescia, Brescia 25123, Italy.
  • Imaging Platform, Department of Molecular and Translational Medicine, University of Brescia, Brescia 25123, Italy.
  • Department of Biological Chemistry, Institute for Advanced Chemistry of Catalonia, Barcelona 08034, Spain.
  • Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Instituto de Salud Carlos III, Madrid 28029, Spain.
  • Department of Health Sciences, Clinical Biochemistry and Mass Spectrometry Lab, San Paolo Hospital, University of Milan, Milan 20142, Italy.

ORCID-Profile: Marco Presta

Förderung

  • Associazione Italiana per la Ricerca sul Cancro
  • Next Generation EU
  • Fondazione Berlucchi

Zitieren

APA

Guerra, J., Belleri, M., Scalvini, E., Capoferri, D., Tobia, C., Ravelli, C., Corli, M., Bresciani, N., Casas, J., Fabrias, G., Dei Cas, M., Presta, M., & Mignani, L. (2025). Brain accumulation of lactosylceramide characterizes GALC deficiency in a zebrafish model of Krabbe disease. Brain, 148(10), 3748-3762. https://doi.org/10.1093/brain/awaf150

Vancouver

Guerra J, Belleri M, Scalvini E, Capoferri D, Tobia C, Ravelli C, et al. Brain accumulation of lactosylceramide characterizes GALC deficiency in a zebrafish model of Krabbe disease. Brain. 2025;148(10):3748-3762. doi:10.1093/brain/awaf150

BibTeX
@article{Guerra2025,
  author = {Guerra, Jessica and Belleri, Mirella and Scalvini, Elisa and Capoferri, Davide and Tobia, Chiara and Ravelli, Cosetta and Corli, Marzia and Bresciani, Nicole and Casas, Josefina and Fabrias, Gemma and Dei Cas, Michele and Presta, Marco and Mignani, Luca},
  title = {Brain accumulation of lactosylceramide characterizes GALC deficiency in a zebrafish model of Krabbe disease},
  journal = {Brain},
  year = {2025},
  volume = {148},
  number = {10},
  pages = {3748--3762},
  doi = {10.1093/brain/awaf150}
}
Kostenlos starten →